| Perjeta (pertuzumab) / Roche |
ACTRN12622000016730: HER2Pro 1B - Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously untreated HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study |
|
|
| Recruiting | 1 | 12 | | | University of Queensland, NHMRC Ideas Grant | Metastatic HER2-positive breast cancer | | | | |
NCT02494596: A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 19 | Europe | Capecitabine, Xeloda, RhuMab 2C4, Omnitarg | Hoffmann-La Roche | Solid Tumor | 09/05 | 09/05 | | |
NCT02490475: A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors |
|
|
| Completed | 1 | 19 | Europe | Docetaxel, Taxotere, RhuMab 2C4, Omnitarg | Hoffmann-La Roche | Solid Tumor | 04/06 | 04/06 | | |
NCT02507375: A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Completed | 1 | 17 | Europe | Erlotinib, Tarceva, Pertuzumab, Perjeta | Hoffmann-La Roche | Non-Small Cell Lung Cancer | 12/08 | 12/08 | | |
